CCO Treatment Updates
Improving Survival in Colorectal Cancer Through Optimal Management of Liver Metastases
Module
Liver Metastases in Colorectal Cancer: Improving Survival Through Optimal Management
 
- Jean-Nicolas Vauthey, MD, FACS
- Daria Zorzi, MD
|
|
|
Jean-Nicolas Vauthey, MD, FACS, and Daria Zorzi, MD, review recent advances and current controversies in the treatment of colorectal cancer patients with liver metastases
Learning Objectives
Upon completion of this activity, participants should be able to:
- Define current criteria for resectability of liver metastases in colorectal cancer and contrast these with older criteria
- Discuss the benefits of neoadjuvant and conversion systemic therapy in patients with colorectal cancer and liver metastases
- Identify the possible risks of perioperative chemotherapy in patients with colorectal cancer and liver metastases and steps to reduce these risks
- Define future liver remnant and describe its assessment
- Explain the use and the limitations of radiofrequency ablation in patients with colorectal cancer and liver metastases
|
Interactive Case Challenges
Management of Initially Unresectable Liver Metastases in a 65-Year-Old Woman With Colorectal Cancer
 
- Richard M. Goldberg, MD
- Bert H. O'Neil, MD
|
|
|
In this Interactive Case Challenge, Richard M. Goldberg, MD, and Bert H. O’Neil, MD, explore treatment options for a colorectal cancer patient with liver metastases.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss current criteria for resectability of liver metastases in patients with colorectal cancer and how they differ from past criteria
- Summarize clinical trial data supporting the use of systemic therapy to convert initially unresectable liver metastases to resectability
- Identify risks of neoadjuvant systemic therapy that may influence the feasibility and outcome of curative resection of liver metastases
- Discuss current options for therapy in patients who experience disease recurrence
|
A 52-Year-Old Man With Colon Cancer and Resectable Metachronous Liver Metastases
 
- J. Randolph Hecht, MD
- Zev A. Wainberg, MD
|
|
|
J. Randolph Hecht, MD, and Zev A. Wainberg, MD, explore treatment options for a male with metastasized colon cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss current data on the use of perioperative systemic therapy in patients with resectable colorectal liver metastases
- Describe prospects for long-term survival in patients who undergo resection of colorectal liver metastases
- Summarize data on use of targeted biologic agents in combination with other agents in the treatment of metastatic colorectal cancer
- Explain the rationale for KRAS tumor testing in patients who are candidates for therapy with epidermal growth factor receptor antibodies
|
A 63-Year-Old Woman With Colorectal Cancer and Metachronous Liver and Lung Metastasis
- Jean-Nicolas Vauthey, MD, FACS
- Daria Zorzi, MD
|
|
|
Jean-Nicolas Vauthey, MD, FACS, and Daria Zorzi, MD, present the case of a 63-year-old woman who, after resection of her colorectal tumor, now has multiple liver metastases and a lung lesion. Take on the difficult challenge of managing this patient and learn what steps the faculty members would choose.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify current criteria for resectability of liver and lung metastases in patients with colorectal cancer
- Discuss the use of systemic therapy to convert unresectable liver metastases to resectability in patients with colorectal cancer
- Explain the rationale for staged resections in patients with extensive colorectal cancer metastases
- Define the concept of future liver remnant and explain its clinical significance
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|